Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has entered into a strategic alliance agreement with the Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program (SABIP).
Subscribe to our email newsletter
The goal of the strategic alliance is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between MIT and sanofi-aventis.
The alliance provides sanofi-aventis the opportunity to develop therapeutic, diagnostic and prognostic applications based on the discoveries made during the alliance.
Under the newly announced partnership, the SABIP will support a number of activities over the next 3 years through the granting of Biomedical Innovation Funding Awards.
The financial awards will provide MIT researchers with focused, flexible and rapidly available support to enable innovative research projects for the development of potential healthcare solutions for patients.
Marc Cluzel, EVP of R&D at sanofi-aventis, said: “By bringing together the talents and expertise of MIT researchers, who are leaders in engineering and biological sciences, with the resources of sanofi-aventis, this alliance has the potential to provide innovative solutions to patients such as new drug delivery devices and technologies.”
Claude Canizares, VP of research and associate provost at the MIT, said: “MIT brings strengths in advanced science and engineering relevant to health care and welcomes the opportunity to work with sanofi-aventis on problems of common interest in biomanufacturing, nanotechnology and other areas.”